Author

F. Dubovsky

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Research Focus:benchmarking· 1 Organism:human· 1 Organism:mouse· 1 Organism:non-human primate· 1 Assay:proteomics· 1

Frequent Co-Authors

G. Smith· 2 shared A. M. Greene· 1 shared A. M. Marchese· 1 shared B. F. Haynes· 1 shared B. Korber· 1 shared C. McDana· 1 shared D. Jiang· 1 shared D. Li· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

G. Smith

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

XBB.1.5 Spike Protein COVID-19 Vaccine Induces Broadly Neutralizing and Cellular Immune Responses Against EG.5.1 and Emerging XBB Variants

N. Patel, J. F. Trost, M. Guebre-Xabier, H. Zhou, J. Norton, D. Jiang, Z. Cai, M. Zhu, A. M. Marchese, A. M. Greene, R. M. Mallory, R. Kalkeri, F. Dubovsky, G. Smith

This study shows that a monovalent XBB.1.5 spike protein vaccine induces broader neutralizing antibodies and stronger cellular immunity against multiple SARS-CoV-2 variants compared to bivalent vaccines.

bioRxiv · Aug 30, 2023Immunology

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines

X. Shen, H. Tang, C. McDana, K. Wagh, W. Fischer, J. Theiler, H. Yoon, D. Li, B. F. Haynes, K. O. Saunders, S. Gnanakaran, N. W. Hengartner, R. Pajon, G. Smith, F. Dubovsky, , D. Montefiori

This study shows that B.1.1.7 SARS-CoV-2 variant remains neutralizable by antibodies from ancestral Spike vaccines and convalescent sera, though with reduced efficacy.

bioRxiv · Jan 27, 2021Immunology